Eloxx Pharmaceuticals Provides Program Updates on ELX-02 and ZKN-013

All 3 Alport patients (100% response rate) treated with ELX-02 had biopsy-confirmed disease regression. Post-treatment UPCR rebound in one patient confirms on-treatment remission was drug-related. IND application submitted to US FDA for ELX-02 in nonsense mutation Alport syndrome. View original press release →

The release as fetched from its publisher. eloxxpharma.com ↗